Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04024072 · ClinicalTrials.gov registry record · Phase 3
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
A Phase 3 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 495
- Enrollment target
NCT04024072 is a Phase 3 study that has completed, run by Padagis. The registered enrollment target is 495 participants.
The verdict
NCT04024072, a Phase 3 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 495 participants
- Enrollment target
Study Summary
To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
Interventions
- DRUG Brinzolamide 1% ophthalmic suspension
- DRUG Azopt 1% Ophthalmic Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04024072
The ClinicalTrials.gov registry entry for NCT04024072 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 495 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brinzolamide 1% ophthalmic suspension is the first listed.
NCT04024072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04024072 about?
NCT04024072 is a clinical study titled "To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes". To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
What is the current status of trial NCT04024072?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 495 participants. The study started on 2019-06-24. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT04024072?
The interventions under investigation include: Brinzolamide 1% ophthalmic suspension (DRUG), Azopt 1% Ophthalmic Suspension (DRUG).
Who is sponsoring clinical trial NCT04024072?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.